SCHEMBL25217387

SCHEMBL25217387

COc1ccc(C(=O)N2CCC3(CCN(CC=O)CC3)CC2)cc1N1CCC(=O)NC1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 5/20 0.45
▸ USP2 O75604 3/20 0.45
▸ CYP3A4 P08684 4/20 0.43
▸ TSHR P16473 4/20 0.43
▸ KCNH2 Q12809 5/20 0.42
▸ CCR8 P51685 4/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ MLKL Q8NB16 1/20 0.42
▸ CRBN Q96SW2 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ CYP2C9 P11712 3/20 0.41
▸ SOS1 Q07889 2/20 0.41
▸ NR3C1 P04150 1/20 0.41
▸ PGR P06401 1/20 0.41
▸ SLC6A4 P31645 1/20 0.41
▸ PDE3B Q13370 1/20 0.41
▸ PDE3A Q14432 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ TNKS O95271 1/20 0.39
▸ PARP1 P09874 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29387309 1.00 CYP2D6 (0.45) CYP2D6USP2CYP3A4TSHRKCNH2
SCHEMBL30430021 0.94 CYP2D6 (0.39) CYP2D6USP2CYP3A4TSHRKCNH2
SCHEMBL25211930 0.94 CYP2D6 (0.43) CYP2D6USP2CYP3A4TSHRKCNH2
SCHEMBL25249471 0.94 CYP2D6 (0.39) CYP2D6USP2CYP3A4TSHRKCNH2
SCHEMBL30430820 0.94 CYP2D6 (0.43) CYP2D6USP2CYP3A4TSHRKCNH2
SCHEMBL25270082 0.93 NR3C1 (0.47) TSHRKCNH2SMN1; SMN2NR3C1PGR
SCHEMBL30158156 0.93 NR3C1 (0.47) TSHRKCNH2SMN1; SMN2NR3C1PGR
SCHEMBL25236749 0.91 CYP2D6 (0.44) CYP2D6USP2CYP3A4TSHRKCNH2
SCHEMBL30267289 0.91 CYP2D6 (0.44) CYP2D6USP2CYP3A4TSHRKCNH2
SCHEMBL25314195 0.90 CYP2D6 (0.42) CYP2D6USP2CYP3A4TSHRKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 — — US disclosed
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 — — US disclosed
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 — — US disclosed
EP-4194457-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) 2023-06-14 — — EP disclosed
EP-4194457-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) 2023-06-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF IRAK4, IRAK2, IRAK1 CYP2D6 2818/4885USP2 431/4885CYP3A4 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback